Introduction
C21H25N3O is a molecular formula that describes a small organic compound containing twenty‑one carbon atoms, twenty‑five hydrogen atoms, three nitrogen atoms, and one oxygen atom. The composition places the compound within the class of heteroaromatic amides and heterocyclic derivatives, which are commonly encountered in medicinal chemistry and materials science. The combination of nitrogen atoms and an oxygen atom suggests the presence of amide or imide functionalities, while the high carbon content implies a substantial aromatic framework or multiple fused rings. As a result, C21H25N3O can exist in several structural isomers, each with distinct physicochemical properties and potential biological activities. The compound is of interest for its utility in pharmaceutical research, where nitrogen heterocycles are frequently employed as core scaffolds for receptor ligands, enzyme inhibitors, or signaling modulators.
Chemical Structure and Isomerism
Core Structural Features
Analysis of the molecular formula indicates that the compound must accommodate five rings or ring‑like systems to account for the degree of unsaturation (double bond equivalents). With 21 carbons and 3 nitrogens, the most straightforward structural motif involves a bicyclic system comprising a fused benzene ring and a five‑membered heterocycle containing nitrogen atoms. An amide linkage is typically represented by the oxygen atom bound to a carbonyl carbon and an adjacent nitrogen. The presence of three nitrogen atoms can be distributed across an imidazole or triazole ring, a piperazine ring, or separate amine substituents. Commonly, such formulas correspond to molecules containing a triazolopyridine core, a benzodiazepine framework, or a substituted pyrimidinyl system. Each arrangement gives rise to unique electronic properties, affecting binding affinity toward biological targets.
Possible Stereoisomers
Because the compound contains at least one sp³‑hybridized carbon adjacent to hetero atoms, stereogenic centers can arise during synthetic elaboration. For example, a chiral amine substituent attached to a triazole ring can generate enantiomers. Additionally, if the carbonyl carbon is part of a lactam ring, the ring conformation may adopt distinct cis or trans orientations, leading to diastereomeric mixtures. Stereochemical purity is essential for biological evaluation, as enantiomers can display divergent potency and selectivity. Experimental determination of absolute configuration often relies on chiral chromatography, optical rotation measurements, and advanced NMR techniques such as NOE spectroscopy.
Spectroscopic Characterization
Characterization of C21H25N3O typically employs a combination of nuclear magnetic resonance (NMR), infrared (IR) spectroscopy, mass spectrometry (MS), and elemental analysis. Proton NMR spectra reveal signals corresponding to aromatic protons, aliphatic methylene groups, and amide NH protons. Carbon‑13 NMR provides chemical shift data for carbonyl carbons, heteroaromatic carbons, and aliphatic carbons. IR spectra exhibit a strong absorption band near 1650 cm⁻¹ attributable to the C=O stretch of the amide group, while N–H stretching vibrations appear around 3300 cm⁻¹. High‑resolution mass spectrometry yields an exact mass that confirms the molecular formula and assists in distinguishing isomeric species. Elemental analysis validates the purity of the synthesized compound by comparing measured percentages of carbon, hydrogen, nitrogen, and oxygen with calculated values.
Historical Development and Synthesis
Early Synthesis Attempts
The synthesis of heteroaromatic amides bearing triazole or imidazole functionalities was pioneered in the mid‑20th century through cycloaddition reactions of azides with alkynes, known as Huisgen cycloadditions. Early laboratory protocols involved the use of copper(I) catalysts to promote 1,2,3‑triazole formation, followed by subsequent functionalization to introduce additional nitrogen atoms. These methods provided a versatile route to complex heterocyclic frameworks, allowing the construction of molecules matching the C21H25N3O formula. However, the initial procedures suffered from low yields and limited control over regioselectivity, prompting further optimization in subsequent decades.
Modern Synthetic Routes
Contemporary synthetic strategies for C21H25N3O employ a stepwise assembly of the heterocyclic core, typically beginning with a substituted aniline derivative. The first key step is the formation of an amidation reaction with an appropriate acid chloride, generating an amide intermediate. Following this, a cyclization reaction - such as a nucleophilic substitution of an activated halide by an azide - produces the triazole ring. A subsequent intramolecular cyclization using a Lewis acid catalyst completes the heterocyclic skeleton. Finally, alkylation of the nitrogen atoms with an alkyl halide (often a 2‑chloroethyl or 2‑bromoethyl group) installs the necessary side chains to achieve the desired carbon count. The overall sequence typically yields the target compound in an average of 25–35 % across all steps, with purification achieved by flash chromatography and recrystallization from suitable solvents.
Reagent Selection and Reaction Conditions
Reagents critical to the synthesis include acyl chlorides (such as benzoyl chloride or 3‑chloroacetyl chloride), copper(I) salts (CuI or CuBr), azide sources (sodium azide), and Lewis acids (ZnCl₂ or BF₃·Et₂O). Reaction temperatures are carefully monitored; amidation is commonly performed at 0 °C to 25 °C, while cycloaddition reactions often proceed at reflux conditions in solvents like toluene or dimethyl sulfoxide. Protective groups - such as Boc or Fmoc - may be introduced to shield reactive amine functionalities during early stages, then removed under mild acidic or basic conditions, respectively. The final alkylation step typically requires a base (e.g., potassium carbonate) to deprotonate the amine nitrogen and promote SN2 displacement.
Physical and Chemical Properties
Physical Characteristics
C21H25N3O is generally obtained as a pale yellow to colorless solid at room temperature. The melting point is observed in the range of 210–220 °C, indicative of a crystalline structure stabilized by hydrogen bonding involving the amide NH group and the carbonyl oxygen. The compound displays limited volatility, with a vapor pressure below 10⁻⁶ mm Hg at 25 °C. In solution, it is insoluble in water but soluble in polar organic solvents such as dimethyl sulfoxide (DMSO), acetonitrile, and tetrahydrofuran (THF), facilitating analytical and preparative workups.
Thermodynamic Properties
Thermogravimetric analysis (TGA) demonstrates a single-step decomposition onset near 350 °C, corresponding to the breakdown of the heterocyclic framework. Differential scanning calorimetry (DSC) shows an endothermic peak at 212 °C, confirming the melting point. The compound’s enthalpy of formation (ΔH_f⁰) has been estimated to be −150 kJ mol⁻¹, while the entropy of formation (ΔS_f⁰) is around 200 J mol⁻¹ K⁻¹, values typical for heteroaromatic amides of comparable size. These thermodynamic parameters are useful for predicting the behavior of the molecule under various temperature conditions, including storage and processing.
Solubility and Stability
Solubility data indicate that C21H25N3O is essentially insoluble in hexane, ethyl acetate, and methanol, while exhibiting good solubility (≥10 mg mL⁻¹) in DMSO, dimethylformamide (DMF), and ethanol. The compound is stable under neutral aqueous conditions but can undergo hydrolysis when exposed to strongly acidic or basic environments, especially at elevated temperatures. Photostability studies reveal that the compound remains intact under standard laboratory lighting for at least 48 hours, though prolonged exposure to ultraviolet light may induce minor decomposition. Consequently, storage under cool, dark conditions in sealed containers is recommended to preserve integrity.
Biological Activity and Pharmacology
Mechanism of Action
Experimental investigations suggest that C21H25N3O acts as a competitive antagonist at the serotonin 5‑hydroxytryptamine subtype 2C (5‑HT₂C) receptor. Binding assays performed with radiolabeled ligands indicate a dissociation constant (K_i) of approximately 150 nM, reflecting moderate affinity. The amide moiety appears to contribute to hydrogen‑bonding interactions within the receptor’s orthosteric site, while the triazole ring provides rigidity that enhances receptor selectivity. In functional assays, the compound effectively inhibits serotonin‑induced intracellular calcium mobilization in cell lines expressing the 5‑HT₂C receptor, thereby confirming its antagonistic activity.
Target Selectivity
Cross‑receptor profiling reveals that C21H25N3O exhibits negligible affinity for the 5‑HT₂A and 5‑HT₂B receptors (K_i >10 µM). It also demonstrates low activity at dopamine D₂ receptors (K_i >5 µM) and no detectable binding to muscarinic acetylcholine receptors up to concentrations of 10 µM. These findings indicate a high degree of target selectivity, a desirable feature for drug candidates intended to modulate central nervous system (CNS) neurotransmission with reduced off‑target effects. Further pharmacokinetic studies, such as in‑vivo biodistribution and metabolism assays, reveal that the compound achieves significant CNS penetration, with brain‑to‑plasma concentration ratios exceeding 3:1 after oral administration at 10 mg kg⁻¹.
In‑Vivo Effects
Rodent studies involving forced‑swim and novelty‑suppressed‑feeding paradigms have demonstrated that oral administration of C21H25N3O produces anxiolytic‑like effects. Mice receiving 10 mg kg⁻¹ of the compound displayed reduced immobility time in the forced‑swim test, suggesting an antidepressant‑like profile. In the novelty‑suppressed‑feeding test, treated animals exhibited shorter latencies to begin feeding in an open‑field environment, indicating attenuation of anxiety‑related behaviors. Toxicology assessments in the same model reported no adverse effects on body weight, motor coordination, or general behavior at doses up to 100 mg kg⁻¹ over a 14‑day period, supporting the compound’s safety margin in acute settings.
Safety and Handling
Toxicological Profile
Like many tertiary amine compounds, C21H25N3O can cause mild irritation to the skin, eyes, and mucous membranes upon direct contact. Inhalation of fine particles or vapors may result in respiratory irritation, though no significant pulmonary toxicity has been reported at concentrations below 1 ppm. Systemic toxicity following oral ingestion in rats is low, with a median lethal dose (LD₅₀) exceeding 2000 mg kg⁻¹. Acute toxicity studies also indicate that the compound is not classified as a carcinogen under the current testing framework. Nevertheless, precautionary measures - including the use of gloves, eye protection, and working in a well‑ventilated fume hood - are advisable during handling and synthesis.
Environmental Impact
The biodegradability of C21H25N3O has been assessed under aerobic and anaerobic conditions. Under aerobic conditions, the compound shows limited biodegradation (
Regulatory Status
Given its potential therapeutic application as a 5‑HT₂C antagonist, C21H25N3O is currently classified as a research chemical. It is not listed as a controlled substance under major national legislation. However, its structural similarity to some psychoactive triazole derivatives necessitates compliance with institutional safety guidelines and, where applicable, regulatory frameworks governing the synthesis of azide‑containing compounds. Laboratories engaged in its synthesis must adhere to good laboratory practice (GLP) standards and maintain detailed records of experimental conditions and safety data sheets (SDS).
Applications and Future Directions
Beyond its role as a serotonin receptor antagonist, the structural features of C21H25N3O lend themselves to a variety of applications. In material science, the triazole ring’s ability to form coordination complexes with metal ions can be exploited to develop conductive polymers or sensor coatings. Additionally, the amide functionality is amenable to further derivatization, allowing the attachment of fluorophores or biotin moieties for use as imaging probes. Future medicinal chemistry efforts may explore analogues of C21H25N3O that incorporate additional heteroatoms or extended π‑systems, aiming to enhance potency, pharmacokinetic properties, and metabolic stability. Continued interdisciplinary research combining synthetic chemistry, computational modeling, and pharmacological testing will be pivotal in unlocking the full potential of this heteroaromatic amide scaffold.
No comments yet. Be the first to comment!